In the first half of 2011, Zentiva posted profit of RON30.5 million and sales of RON120.94 million.
Total revenues in the first six months of 2012 climbed by 12.7%, to RON152.99 million, while expenses increased by 27.8%, to RON126.41 million.
French pharmaceutical company Sanofi-Aventis owns 74.9% of Zentiva, according to the latest information.
On August 14 on the Bucharest stock exchange, Zentiva’s shares traded at RON0.78. (EUR1=RON4.5186)